Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 5/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847189 | 1.00 | KDM4E (0.43) | KDM4ESLC6A7OPRM1OPRL1PTPN11 | |
| SCHEMBL2847902 | 0.73 | OPRL1 (0.40) | KDM4ESLC6A7OPRM1OPRL1MEN1 | |
| SCHEMBL2847899 | 0.73 | OPRL1 (0.40) | KDM4ESLC6A7OPRM1OPRL1MEN1 | |
| SCHEMBL26156915 | 0.72 | KDM4E (0.36) | KDM4ESLC6A7MEN1KMT2ACYP3A4 | |
| SCHEMBL1020867 | 0.72 | SLC6A7 (0.35) | KDM4ESLC6A7PTPN11CYP3A4CYP2D6 | |
| SCHEMBL18081206 | 0.72 | OPRM1 (0.45) | KDM4ESLC6A7OPRM1CYP2C19 | |
| SCHEMBL3579782 | 0.68 | SLC6A7 (0.37) | KDM4ESLC6A7MEN1KMT2ACYP2C19 | |
| SCHEMBL3205032 | 0.68 | CYP3A4 (0.53) | KDM4EPTPN11MEN1KMT2ACYP3A4 | |
| SCHEMBL20009032 | 0.68 | SLC6A7 (0.38) | KDM4ESLC6A7OPRM1CYP2C19 | |
| SCHEMBL20064101 | 0.67 | ALDH1A1 (0.48) | KDM4EMEN1KMT2ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| EP-1664031-B1 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | SANOFI-AVENTIS (FR) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | DPP4, DPP7, DPP9 | KDM4E 886/4885SLC6A7 356/4885OPRM1 3387/4885 |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | DPP4, DPP7, DPP9 | KDM4E 886/4885SLC6A7 356/4885OPRM1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.